More than 430 New Medicines in Development for Chronic Diseases
PhRMA announced 430 new medicines in development to treat chronic diseases affecting older Americans.
According to a new report by the
(PhRMA), America’s biopharmaceutical research companies are developing 435 new medicines to target 15 leading chronic conditions affecting the Medicare population. These medicines in development include: 110 for diabetes, 62 for rheumatoid arthritis and osteoarthritis, 67 for Alzheimer’s disease, 61 for heart disease (i.e., heart failure, hypertension, ischemic heart disease and high cholesterol), and 40 for chronic obstructive pulmonary disease (COPD).
Approximately 92% of older adults have at least one chronic condition and 77% have at least two, according to the National Council on Aging. The new report conveys a variety of new approaches to treat many of these disorders. Examples include: a potential new class of lipid-lowering treatments that would block a protein from interfering with the removal of LDL cholesterol from the blood; a medicine in development for heart failure that relaxes blood vessels and reduces fluid buildup, that could reduce damage to the heart and other vital organs related to the damage associated with heart failure; a long-acting oral medicine to treat type 2 diabetes that increases insulin secretion resulting in lower blood sugar levels, making it potentially a once-weekly versus daily treatment; a potential medicine for Alzheimer’s disease that inhibits beta-site amyloid precursor protein cleaving enzyme, that could reduce plaque formation and modify Alzheimer’s disease progression.
Source:
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
